Published Date: 31 Jul 2023
With a five-year survival rate of less than 20%, esophageal adenocarcinoma (EAC) is a highly fatal cancer. Despite being an EAC precursor lesion,.
Read Full NewsAlmost immediately after Theresa Greco was diagnosed with breast cancer in March, doctors asked her whether she wanted to participate in a clinical trial. The trial would do high-powered radiation targeted at her tumor prior ...
Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting the protein essential to tumor cell growth and by adding a key signal to boost the immune system response. ...
Indoor hydroponic gardening—a method of growing plants using nutrient-rich water instead of soil—could help cancer patients develop better mental health, eat a healthier diet and enjoy a better overall quality of life.
In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older.
1.
Survey shows cancer anxiety has impact well beyond the individual diagnosed
2.
Trump Issues Gag Order for CDC, FDA; Stalled Hearing for RFK Jr.; Sex After Cancer
3.
Could semaglutide be used to treat addiction in addition to obesity?
4.
Study sheds light on challenges for women of color after breast cancer surgery
5.
FDA Authorizes Three Different Uses for Injectable Antibiotic.
1.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
2.
Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment
3.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
4.
Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights
5.
Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
5.
Navigating the Complexities of Ph Negative ALL - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation